Literature DB >> 12411786

Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes.

Yoshitatsu Sei1, Barbara W Brandom, Saiid Bina, Eiji Hosoi, Kathleen L Gallagher, Hadley W Wyre, Paul A Pudimat, Steve J Holman, David J Venzon, John W Daly, Sheila Muldoon.   

Abstract

BACKGROUND: Altered Ca2+ homeostasis in skeletal muscle is a key molecular event triggering malignant hyperthermia (MH) in malignant hyperthermia-susceptible (MHS) individuals. Genetic studies have shown that mutations in the type 1 ryanodine receptor (RYR1) are associated with MH susceptibility. Because human B lymphocytes express the RYR1, it is hypothesized that Ca2+ homeostasis in B lymphocytes is altered in MHS individuals.
METHODS: This study investigated the Ca2+ response of B cells to caffeine and 4-chloro-m-cresol in 13 MHS and 21 MH-negative (MHN) individuals who had been diagnosed by caffeine halothane contracture test (CHCT) and 18 healthy volunteers. Changes in [Ca2+]i in B cells were measured directly in fluo-3 loaded cells using a dual-color flow cytometric technique. Further, B cell phenotype was correlated with CHCT results in a family with the Val2168Met (G6502A) mutation.
RESULTS: Caffeine-induced (50 mm) increases in [Ca2+]i in B cells were significantly greater in MHS than in MHN (P = 0.0004), control (P = 0.0001) or non-MHS (MHN and control) individuals (P < 0.0001). The 4-chloro-m-cresol-induced (400 microm) increases in [Ca2+]i were also significantly different between MHS and controls (P = 0.003) or between MHS and non-MHS (MHN and control) individuals (P = 0.0078). A study of a family with the Val2168Met mutation demonstrated expression of the RYR1 mRNA mutant in B cells from the family members with MHS phenotype and a clear segregation of genotype with B-cell phenotype.
CONCLUSION: The Ca2+ responses to caffeine or 4-chloro-m-cresol in B lymphocytes showed significant differences between MHS and MHN (or control) individuals. Although the molecular mechanisms of these alterations are currently undetermined, the results suggest that the enhanced Ca2+ responses are associated with mutations in the RYR1 gene in some MHS individuals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411786     DOI: 10.1097/00000542-200211000-00005

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  8 in total

1.  Ryanodine Receptor Calcium Leak in Circulating B-Lymphocytes as a Biomarker in Heart Failure.

Authors:  Alexander Kushnir; Gaetano Santulli; Steven R Reiken; Ellie Coromilas; Sarah J Godfrey; Danielle L Brunjes; Paolo C Colombo; Melana Yuzefpolskaya; Seth I Sokol; Richard N Kitsis; Andrew R Marks
Journal:  Circulation       Date:  2018-09-11       Impact factor: 29.690

2.  Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95).

Authors:  Tram Anh Ta; Isaac N Pessah
Journal:  Neurotoxicology       Date:  2006-08-30       Impact factor: 4.294

Review 3.  PharmGKB summary: very important pharmacogene information for RYR1.

Authors:  Maria L Alvarellos; Ronald M Krauss; Russell A Wilke; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-03       Impact factor: 2.089

4.  T lymphocytes from malignant hyperthermia-susceptible mice display aberrations in intracellular calcium signaling and mitochondrial function.

Authors:  Lukun Yang; Elena N Dedkova; Paul D Allen; M Saleet Jafri; Alla F Fomina
Journal:  Cell Calcium       Date:  2020-12-01       Impact factor: 6.817

Review 5.  Management of malignant hyperthermia: diagnosis and treatment.

Authors:  Daniel Schneiderbanger; Stephan Johannsen; Norbert Roewer; Frank Schuster
Journal:  Ther Clin Risk Manag       Date:  2014-05-14       Impact factor: 2.423

6.  Hypermetabolism in B-lymphocytes from malignant hyperthermia susceptible individuals.

Authors:  Kerstin Hoppe; Guido Hack; Frank Lehmann-Horn; Karin Jurkat-Rott; Scott Wearing; Alberto Zullo; Antonella Carsana; Werner Klingler
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

Review 7.  Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Authors:  Tokunbor A Lawal; Emily S Wires; Nancy L Terry; James J Dowling; Joshua J Todd
Journal:  Orphanet J Rare Dis       Date:  2020-05-07       Impact factor: 4.123

Review 8.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.